Charlie Rudin

1 Hot off the press from team @MSKCancerCenter in @CD_AACR! A study solving the puzzle of exceptional new lung cancer type: #Chromothripsis-mediated Small Cell Lung Cancer #SCLC This took nearly a decade and 42 coauthors to unravel. Here are some highlights 👇 aacrjournals.org/cancerdiscover…

Now online in @CD_AACR: #Chromothripsis-mediated Small Cell Lung Carcinoma - by @natasharekhtman @SamTTweets @ChrisFebres @charlesrudin and colleagues doi.org/10.1158/2159-8… @MSKCancerCenter #SCLC

@natasharekhtman @MSKCancerCenter @CD_AACR So awesome to collaborate with @natasharekhtman and a great multi-D team on this study!

Inspiration for the August cover art: First-in-human trial of #imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade #neuroendocrinetumours of the lung and prostate thelancet.com/journals/lanon… #NeuroendocrineTumors #SCLC

@TheLancetOncol Thanks to @TheLancetOncol for this cool cover image — DLL3 PET lighting up SCLC in storm seas — great collaboration with @LewisLabMSKCC @Tendler_S JT Poirier and Mark Dunphy! Novel imaging study at @MSKCancerCenter

So excited, our phase 1/2 first in human imaging w/ [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate, is out. JT Poirier @charlesrudin @LewisLabMSKCC @Tendler_S @morr316 @lisabodei et al., sciencedirect.com/science/articl…

with particularly striking declines in incidence and death rates among those under age 50... a harbinger, perhaps. Still much to do!

Are we heading toward a future where #lungcancer is NOT the leading cause of US cancer mortality in either men or women? Data out today in doi.org/10.3322/caac.2… continuing a nice trend --

@DISCOPharma Great to see this going live! Congrats 🎉

Introducing @DISCOPharma! The #surfaceome company. DISCO's mission is to improve treatment options for patients living with cancer by unleashing the full potential of targeted cancer therapies. Find out more: bit.ly/4aSbTkp #drugdiscovery #biotech

@AmericanCancer @DanaFarber Well deserved, Pasi — congratulations!

We are pleased to share that Dr. Pasi A. Jänne of @DanaFarber has been awarded the American Cancer Society 2024 Medal of Honor. This is ACS’s most prestigious award & recognizes those who have made valuable contributions in basic research, cancer control, clinical research & philanthropy. amercancer.co/moh24

@graeber_thomas Great work by Olga Chia-Chun in the Graeber and Witte labs!

Sharing new insight and data on the cancer transdifferentiation therapy resistance escape route. Congratulations to Olga and team for their contributions to the field. linkedin.com/posts/olga-che…

@Samuel_Bakhoum Hello, PACIFIC 2…

Despite best wishes there is no clinically proven synergy between concurrent #Radiation and #immune checkpoint blockade - time to move on

@SageJulien @ZheWang_NCB @NatureCellBio Congrats Julien et al!

Our study on SCLC brain metastasis is out! rdcu.be/dnyzz Thanks again to all, including @ZheWang_NCB @NatureCellBio. A great effort by Fangfei and all the authors since the pre-print was first posted 2 years ago!

@ArielleElkrief @SRC_CRS @MLadanyi @AdamJSchoenfeld @RielyMD @HelenaYu923 @MSKCancerCenter So well deserved, Arielle! Congratulations.

@FNIH_Org Congratulations Vinod! So well deserved: trailblazer indeed.

The FNIH has named Vinod Balachandran, MD, recipient of the 2023 Trailblazer Prize for Clinician-Scientists for his groundbreaking research on new immunotherapies for pancreatic cancer.  Read the full press release here bit.ly/44nZtvV

@YJanjigianMD @ASCO @MSKCancerCenter @MSK_DeptOfMed @RielyMD I remember that talk! You were great.

Congrats Charlie Rudin our new Cancer Center Deputy Director! So bright & kind. We met 15 yrs ago; I was 8 mos pregnant, doing my 1st talk @asco & looking for a job! Charlie was the discussant, his positivity & support settled my nerves & gave a needed confidence boost

@jmchan88 Looking forward to continuing to learn from (and collaborate with) @jmchan88 — sky is the limit!

🎉Exciting News!🧬🔬 I’m starting a computational biology lab at Memorial Sloan Kettering Cancer Center in NYC! We're hiring at all levels to study how histological transformation and other forms of lineage plasticity drive progression across cancer types! joechanlab.org

DLL3 is the target of multiple investigational therapeutic strategies for patients with SCLC and other high-grade NE cancers. A pleasure to review state-of-the-state together with many clinical leaders of the field. jhoonline.biomedcentral.com/articles/10.11…

@RielyMD @alissajcooper @MSK_DeptOfMed Yes indeed! All star. ⭐️ ⭐️ ⭐️

We are excited that Dr @alissajcooper will be joining us on the Thoracic Oncology Service in the @MSK_DeptOfMed @charlesrudin

correction: @LisaHaas0107

A brief reflection on the exceptional fertility of graveyards...(!) Thanks to @NatureCancer and editor @LisaHass0107 for the invitation, and to @MSKCancerCenter and @HopkinsMedicine for supporting the freedom to explore. rdcu.be/dcZQv